How many sputum culture results do we need to monitor multidrug-resistant- tuberculosis (MDR-TB) patients during treatment?

Journal of Clinical Microbiology

Volumn 51, Issue 2, 2013, Pages 644-646

  Janssen, Saskia ^a,b   Padanilam, Xavier ^c   Louw, Rianna ^c   Mahanyele, Russel ^c   Coetzee, Gerrit ^d   Hänscheid, Thomas ^e   Leenstra, Tjalling ^a,f   Grobusch, Martin P ^a,b,g  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c Sizwe Tropical Diseases Hospital   (South Africa)

^d National Reference Laboratory for Tuberculosis   (South Africa)

^e UNIVERSITY OF LISBON   (Portugal)

^f Ministerie van Defensie   (Netherlands)

^g UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ADULT; AMBULATORY CARE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HOSPITAL CARE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PATIENT MONITORING; PATIENT REFERRAL; PRIORITY JOURNAL; PULMONARY VEIN ISOLATION; SOUTH AFRICA; SPUTUM CULTURE; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

ADULT; ANTITUBERCULAR AGENTS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; SPUTUM; TIME FACTORS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84873030474     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02837-12     Document Type: Article

References (12)

1. World Health Organization. 2012. Global tuberculosis report 2012. World Health Organization, Geneva, Switzerland.
2. Grobusch MP. 2010. Drug-resistant and extensively drug-resistant tuberculosis in southern Africa. Curr. Opin. Pulm. Med. 16:180 -185.
3. Laserson KF, Thorpe LE, Leimane V, Weyer K, Mitnick CD, Riekstina V, Zarovska E, Rich ML, Fraser HS, Alarcon E, Cegielski JP, Grzemska M, Gupta R, Espinal M. 2005. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 9:640-645.
4. World Health Organization. 2011. Guidelines for the programmatic management of drug-resistant tuberculosis-2011 update. World Health Organization, Geneva, Switzerland.
5. World Health Organization. 1999. Tuberculosis infection control in the era of expanding HIV care and treatment. Addendum to theWHOGuidelines for the Prevention of Tuberculosis in Health Care Facilities in Resource- Limited Settings. World Health Organization, Geneva, Switzerland.
6. Fitzwater SP, Caviedes L, Gilman RH, Coronel J, LaChira D, Salazar C, Saravia JC, Reddy K, Friedland JS, Moore DA. 2010. Prolonged infectiousness of tuberculosis patients in a directly observed therapy shortcourse program with standardized therapy. Clin. Infect. Dis. 51:371-378.
7. Fortún J, Martin-Davila P, Molina A, Navas E, Hermida JM, Cobo J, Gomez-Mampaso E, Moreno S. 2007. Sputum conversion among patients with pulmonary tuberculosis: are there implications for removal of respiratory isolation? J. Antimicrob. Chemother. 59:794 -798.
8. Holtz TH, Sternberg M, Kammerer S, Laserson KF, Riekstina V, Zarovska E, Skripconoka V, Wells CD, Leimane V. 2006. Time to sputum culture conversion in multidrug-resistant tuberculosis: predictors and relationship to treatment outcome. Ann. Intern. Med. 144:650- 659.
9. Cox H, van Cutsem G. 2011. Household screening and multidrugresistant tuberculosis. Lancet 377:103-104.
10. Sundaram V, Fujiwara PI, Driver CR, Osahan SS, Munsiff SS. 2002. Yield of continued monthly sputum evaluation among tuberculosis patients after culture conversion. Int. J. Tuberc. Lung Dis. 6:238 -245.
11. Kurbatova EV, Gammino VM, Bayona J, Becerra M, Danilovitz M, Falzon D, Gelmanova I, Keshavjee S, Leimane V, Mitnick CD, Quelapio MI, Riekstina V, Taylor A, Viiklepp P, Zignol M, Cegielski JP. 2011. Frequency and type of microbiological monitoring of multidrug-resistant tuberculosis treatment. Int. J. Tuberc. Lung Dis. 15:1553-1556.
12. Becerra MC, Appleton SC, Franke MF, Chalco K, Arteaga F, Bayona J, Murray M, Atwood SS, Mitnick CD. 2011. Tuberculosis burden in households of patients with multidrug-resistant and extensively drugresistant tuberculosis: a retrospective cohort study. Lancet 377:147-152.